

CorMedix Inc.  
Form 8-K  
February 06, 2015

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 6, 2015

CORMEDIX INC.  
(Exact Name of Registrant as  
Specified in Charter)

|  |  |  |
|--|--|--|
| Delaware<br>(State or Other<br>Jurisdiction of<br>Incorporation) | 001-34673<br><br>(Commission File<br>Number) | 20-5894890<br><br>(IRS Employer<br>Identification No.) |
|--|--|--|

745 Rt. 202-206,  
Suite 303,  
Bridgewater, NJ 08807  
(Address of  
Principal  
Executive  
Offices) (Zip  
Code)

Registrant's Telephone Number, Including Area Code: (908) 517-9500

(Former Name or Former Address, If Changed  
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Explanatory Note

CorMedix Inc. is filing this Form 8-K for the sole purpose of filing Exhibit 10.1 hereto in connection with our request to the Staff of the Commission for an extension of the confidential treatment of portions of the Taurolidine Supply Agreement, dated December 7, 2009, by and between us and Navinta, LLC.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

|             |   |
|-------------|---|
| <u>10.1</u> | Taurolidine Supply Agreement, dated December 7, 2009 by and between CorMedix Inc. and Navinta, LLC. |
|-------------|---|

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

February 6, 2015

CORMEDIX INC.

|        |                 |                         |
|--------|-----------------|-------------------------|
| By:    | /s/ Randy Milby |                         |
| Name:  |                 | Randy Milby             |
| Title: |                 | Chief Executive Officer |